Methylation analysis of the recurrent tumor yielded no match to a reference tumor class, yet this is often the case in recurrent tumors after treatment.4 However, the copy-number profile showed a CDKN2A/B deletion typical for PXA and DNA/RNA panel sequencing found no alterations which could have contradicted the diagnosis. This evidence concerns the gene CDKN2A and neoplasm.